Charmaine Lykins Net Worth

Ms. Charmaine Lykins biography

Charmaine Lykins is the Chief Commercial Officer at Karuna Therapeutics Inc.

What's Ms Lykins's mailing address?

Charmaine's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, FLOOR 26, BOSTON, MA, 02110.

Insiders trading at Karuna Therapeutics Inc

Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy y Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.

What does Karuna Therapeutics Inc do?

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip

Karuna Therapeutics Inc executives and stock owners

Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Paul,
  Chairman of the Board, President, Chief Executive Officer
• Andrew Miller,
  Chief Operating Officer
• Edmund Harrigan,
  Independent Director
• Troy Ignelzi,
  Chief Financial Officer
• Dr. Steven M. Paul M.D.,
  CEO, Pres & Chairman
• Dr. Andrew Craig Miller,
  Co-Founder & COO
• Dr. Stephen K. Brannan,
  Chief Medical Officer
• Dr. Troy A. Ignelzi,
  CFO & Sec.
• Stephen Brannan,
  Chief Medical Officer
• Atul Pande,
  Independent Director
• James Healy,
  Independent Director
• Jeffrey Jonas,
  Director
• Heather Preston,
  Independent Director
• Robert Nelsen,
  Independent Director
• Christopher Coughlin,
  Independent Director
• Laurie Olson,
  Director
• Giorgio Attardo,
  Vice President, CMC and Preclinical Development
• Dr. Ronald N. Marcus M.D.,
  Sr. VP of Medical
• Charmaine Lykins,
  Chief Commercial Officer
• Dr. James E. Audia Ph.D.,
  Head of Medicinal Chemistry & Sr. Adviser
• Dr. Alan Breier,
  Chair of Scientific Advisory Board & Chief Clinical Advisor
• Stephanie Moore,
  VP of HR
• Sharon Sawchak R.N.,
  VP of Clinical Operations & Compliance
• Mia Kelley J.D.,
  VP of Legal Affairs
• Jason Parker Brown,
  VP of Corp. Fin.
• Venture Partners Ix, Llcarc...,
  
• William Meury,
  President and CEO
• Bharat M Chowrira,
  Director
• Venture Partners Ix, Llcarc...,
  
• Charmaine Lykins,
  Chief Commercial Officer
• Health Llc Pure Tech,
  
• David E. Wheadon,
  
• Denice Torres,
  
• William P Jr Kane,
  Chief Commercial Officer
• Jason Parker Brown,
  Chief Financial Officer